Connect Biopharma

Connect Biopharma is developing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα for asthma and COPD.

Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2021
Stage of Initial Investment
Series C
Initial Investment Year
2020
Connect Portco Hover Image